✓ Translated by DotMD AI Clinical Council Source: Hypertension research : official journal of the Japanese Society of Hypertension • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #16335883 ↗

Randomized Controlled Trial: Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension (N = 805)

Original Paper Title: “Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 805
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Compared with the L50/H12.5 group, the mean reductions in the last 6-h mean DBP for the T40/H12.5 and T80/H12.5 groups were significantly greater: -2.0 mmHg (p=0.0031) and -2.8 mmHg (p=0.0003), respectively.
  • Study Design & Sample: Randomized Controlled Trial published in Hypertension research : official journal of the Japanese Society of Hypertension (N = 805 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Hypertension research : official journal of the Japanese Society of Hypertension (2005), this randomized controlled trial evaluating 805 human participants investigated: Hypertension is risk factor for cardiovascular morbidity and mortality, and stroke. Key clinical takeaway: Compared with the L50/H12.5 group, the mean reductions in the last 6-h mean DBP for the T40/H12.5 and T80/H12.5 groups were significantly greater: -2.0 mmHg (p=0.0031) and -2.8 mmHg (p=0.0003), respectively.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Hypertension research : official journal of the Japanese Society of Hypertension, 2005-07-15; N = 805; Rigor 87/100): Compared with the L50/H12.5 group, the mean reductions in the last 6-h mean DBP for the T40/H12.5 and T80/H12.5 groups were significantly greater: -2.0 mmHg (p=0.0031) and -2.8 mmHg (p=0.0003), respectively.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: telmisartan → Rx: hydrochlorothiazide → Rx: losartan-potassium → Rx: losartan-potassium-and-hydrochlorothiazide → Condition: phlebitis-and-thrombophlebitis-of-superficial-vessels-of-unspecified → Condition: phlebitis-and-thrombophlebitis-of-unspecified-femoral-vein →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 16335883: Randomized Controlled Trial: Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension (N = 805)

3 of 3 Free Questions Remaining